BDX Stock Analysis: Becton Dickinson | NYSE

Medical Instruments & Supplies | NYSE, USA | Market Cap: 59.389m USD | 12M Return: 46.5% | US0758871091 | Charts, Fundamentals & Technical Analysis

Medical Catheters, Diagnostic Systems, Drug Delivery, Surgical Instruments
Total Rating 67
Safety 85
Buy Signal 1.05
Health Care Equipment
Sub-Industry Rotation: -4.8
Market Cap: 59.4B
Avg Turnover: 391M
Risk 3d forecast
Volatility23.0%
VaR 5th Pctl3.57%
VaR vs Median-5.99%
Reward TTM
Sharpe Ratio1.43
Rel. Str. IBD92.8
Rel. Str. Peer Group71.9 pctl
Character TTM
Beta0.241
Beta Downside0.101
Hurst Exponent0.501
Choppyness20.5%
Drawdowns 3y
Max DD33.39%
CAGR/Max DD0.22
CAGR/Mean DD0.62
EPS (Earnings per Share) EPS (Earnings per Share) of BDX over the last years for every Quarter: "2021-09": 2.59, "2021-12": 3.64, "2022-03": 3.18, "2022-06": 2.66, "2022-09": 2.75, "2022-12": 2.98, "2023-03": 2.86, "2023-06": 2.96, "2023-09": 3.42, "2023-12": 2.68, "2024-03": 3.17, "2024-06": 3.5, "2024-09": 3.81, "2024-12": 3.43, "2025-03": 3.35, "2025-06": 3.68, "2025-09": 3.96, "2025-12": 2.91, "2026-03": 2.9, "2026-06": 3.23, "2026-09": 4.15,
EPS CAGR: 3.44%
EPS Trend: 50.5%
Last SUE: 0.66
Qual. Beats: 0
Revenue Revenue of BDX over the last years for every Quarter: 2021-09: 5135, 2021-12: 4718, 2022-03: 4750, 2022-06: 4641, 2022-09: 4761, 2022-12: 4586, 2023-03: 4821, 2023-06: 4878, 2023-09: 5087, 2023-12: 4706, 2024-03: 5045, 2024-06: 4990, 2024-09: 5437, 2024-12: 5168, 2025-03: 5272, 2025-06: 5509, 2025-09: 5890, 2025-12: 5252, 2026-03: 4714, 2026-06: 4983, 2026-09: 5274,
Rev. CAGR: 2.89%
Rev. Trend: 64.6%
Last SUE: 2.81
Qual. Beats: 2

Warnings

No concerns identified

Tailwinds

Supp Ema8
Rs Leader
Calm

Seasonality 11.9 years of data, until 10/2026

Jan +2.7% 21
Feb -1.0% 14
Mar -0.1% 0
Apr -1.0% 0
May -2.0% 47
Jun +0.8% 14
Jul +3.0% 47
Aug +0.1% 0
Sep -2.9% 100
Oct -0.7% 4
Nov +1.4% 9
Dec -0.1% 0

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.

Description: BDX Becton Dickinson

Becton, Dickinson and Company (BDX) is a large-cap U.S. medical technology company that develops, manufactures, and sells a broad portfolio of medical supplies, devices, laboratory instruments, and diagnostic products to healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical companies, and the general public worldwide. The company operates through four segments: Medical Essentials, Connected Care, BioPharma Systems, and Interventional and Life Sciences.

Its product offerings span vascular access and infusion therapy products (IV catheters, central lines, needle-free connectors, infusion systems, pharmacy automation), drug delivery systems (prefillable syringes, closed-system drug transfer devices), diagnostics (automated blood and TB culturing, molecular testing, microbiology lab automation, clinical oncology and immunology reagents), life science research tools (flow cytometers, single-cell gene expression solutions), and surgical and interventional products (hernia and soft tissue repair, biosurgery, peripheral intervention, urology). BDX also maintains a strategic collaboration with ChemoGLO to advance hazardous drug contamination testing in healthcare settings.

As a diversified medical device manufacturer, BDX benefits from cross-selling opportunities across its four segments and a recurring revenue base driven by high-volume consumables such as syringes, needles, and blood collection products. The medical device industry is characterized by lengthy regulatory approval cycles, significant R&D investment, and stable demand tied to healthcare utilization rather than economic cycles. BDXs segment structure allows it to participate across the full continuum of care, from pharmaceutical development and bioprocessing through clinical diagnostics, drug delivery, and surgical intervention.

Headlines to Watch Out For
  • Connected Care medication management revenue accelerates on hospital automation demand
  • Interventional segment margins pressured by post-pandemic elective procedure normalization
  • Prefillable syringe demand surges from GLP-1 obesity drug manufacturers
Piotroski VR-10 (Strict) 5.5
Net Income: 1.14b TTM > 0 and > 6% of Revenue
FCF/TA: 0.05 > 0.02 and ΔFCF/TA 0.62 > 1.0
NWC/Revenue: -6.07% < 20% (prev 4.31%; Δ -10.38% < -1%)
CFO/TA 0.07 > 3% & CFO 3.44b > Net Income 1.14b
Net Debt (15.6b) to EBITDA (4.74b): 3.30 < 3
Current Ratio: 0.87 > 1.5 & < 3
Outstanding Shares: last quarter (274.1m) vs 12m ago -4.55% < -2%
Gross Margin: 47.01% > 18% (prev 45.44%; Δ 1.56% > 0.5%)
Asset Turnover: 38.12% > 50% (prev 39.47%; Δ -1.36% > 0%)
Interest Coverage Ratio: 4.83 > 6 (EBIT TTM 2.50b / Interest Expense TTM 518.0m)
Altman Z'' 2.27
A: -0.02 (Total Current Assets 8.32b - Total Current Liabilities 9.54b) / Total Assets 50.8b
B: 0.34 (Retained Earnings 17.5b / Total Assets 50.8b)
C: 0.05 (EBIT TTM 2.50b / Avg Total Assets 53.1b)
D: 0.95 (Book Value of Equity 24.7b / Total Liabilities 26.1b)
Altman-Z'' = 2.27 = BBB
Beneish M -3.11
DSRI: 1.00 (Receivables 2.77b/2.99b, Revenue 20.2b/21.8b)
GMI: 0.97 (GM 45.44% / 47.01%)
AQI: 1.01 (AQ_t 0.71 / AQ_t-1 0.71)
SGI: 0.93 (Revenue 20.2b / 21.8b)
TATA: -0.05 (NI 1.14b - CFO 3.44b) / TA 50.8b)
Beneish M = -3.11 (Cap -4..+1) = AA
What is the price of BDX shares?

As of November 19, 2026, the stock is trading at USD 216.08 with a total of 1,316,147 shares traded. Over the past week, the price has changed by +0.73%, over one month by +13.29%, over three months by +20.24% and over the past year by +46.48%.

Current recommended Stop Loss: 210.70 (which is 2.5% or 1.2 ATR below the current price).

Is BDX a buy, sell or hold?

Becton Dickinson has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy BDX.

  • StrongBuy: 8
  • Buy: 1
  • Hold: 6
  • Sell: 1
  • StrongSell: 0

What are the forecasts/targets for the BDX price?
Analysts Target Price 226.1 4.7%
Becton Dickinson (BDX) - Fundamental Data Overview as of 15 November 2026
Market Cap USD = 59.4b (59.4b USD * 1.0 USD.USD)
P/E Trailing = 42.6673
P/E Forward = 16.2075
P/S = 3.0523
P/B = 2.3805
P/EG = 0.9859
Revenue TTM = 20.2b USD
EBIT TTM = 2.50b USD
EBITDA TTM = 4.74b USD
Long Term Debt = 13.5b USD (from longTermDebt, two quarters ago)
Short Term Debt = 2.92b USD (from shortTermDebt, last quarter)
Debt = 16.3b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.6b USD (calculated: Debt 16.3b - CCE 733.0m)
Enterprise Value = 75.0b USD (59.4b + Debt 16.3b - CCE 733.0m)
Interest Coverage Ratio = 4.83 (Ebit TTM 2.50b / Interest Expense TTM 518.0m)
EV/FCF = 27.10x (Enterprise Value 75.0b / FCF TTM 2.77b)
FCF Yield = 3.69% (FCF TTM 2.77b / Enterprise Value 75.0b)
FCF Margin = 13.69% (FCF TTM 2.77b / Revenue TTM 20.2b)
Net Margin = 5.66% (Net Income TTM 1.14b / Revenue TTM 20.2b)
Gross Margin = 47.01% ((Revenue TTM 20.2b - Cost of Revenue TTM 10.7b) / Revenue TTM)
Gross Margin QoQ = 51.06% (prev 46.46%)
Tobins Q-Ratio = 1.48 (Enterprise Value 75.0b / Total Assets 50.8b)
Interest Expense / Debt = 3.17% (Interest Expense 518.0m / Debt 16.3b)
Taxrate = 24.89% (493.0m / 1.98b)
NOPAT = 1.88b (EBIT 2.50b * (1 - 24.89%))
Current Ratio = 0.87 (Total Current Assets 8.32b / Total Current Liabilities 9.54b)
Debt / Equity = 0.66 (Debt 16.3b / totalStockholderEquity, last quarter 24.7b)
Debt / EBITDA = 3.30 (Net Debt 15.6b / EBITDA 4.74b)
Debt / FCF = 5.64 (Net Debt 15.6b / FCF TTM 2.77b)
Total Stockholder Equity = 24.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.16% (Net Income 1.14b / Total Assets 50.8b)
RoE = 4.65% (Net Income TTM 1.14b / Total Stockholder Equity 24.6b)
RoCE = 6.55% (EBIT 2.50b / Capital Employed (Equity 24.6b + L.T.Debt 13.5b))
RoIC = 4.32% (NOPAT 1.88b / Invested Capital 43.4b)
WACC = 5.58% (E(59.4b)/V(75.7b) * Re(6.46%) + D(16.3b)/V(75.7b) * Rd(3.17%) * (1-Tc(0.25)))
Discount Rate = 6.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -91.94 | Cagr: -2.52%
[DCF] Terminal Value 75.91% ; FCFF base≈2.73b ; Y1≈2.82b ; Y5≈3.18b
[DCF] Fair Price = 122.9 (EV 49.1b - Net Debt 15.6b = Equity 33.5b / Shares 272.4m; r=8.35% [WACC [floored]]; 5y FCF grow 3.67% → 2.50% )
EPS Correlation: 50.48 | EPS CAGR: 3.44% | SUE: 0.66 | # QB: 0
Revenue Correlation: 64.57 | Revenue CAGR: 2.89% | SUE: 2.81 | # QB: 2
EPS current Quarter (2026-12-31): EPS=2.35 | Chg30d=-14.16% | Revisions=-73% | Analysts=11
EPS next Quarter (2027-03-31): EPS=3.03 | Chg30d=-0.56% | Revisions=-10% | Analysts=11
EPS current Year (2027-09-30): EPS=13.22 | Chg30d=-0.65% | Revisions=+15% | GrowthEPS=+4.1% | GrowthRev=+1.7%
EPS next Year (2028-09-30): EPS=14.23 | Chg30d=+0.35% | Revisions=+42% | GrowthEPS=+7.6% | GrowthRev=+4.2%
[Analyst] Revisions Ratio: -5% (up=16, down=18)